Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
KENGREAL (cangrelor) for Injection is a P2Y12 platelet inhibitor indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce risk of MI, repeat coronary revascularization, and stent thrombosis (ST) in patients.
Lead Product(s): Cangrelor
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Kengreal
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
In the multicenter, double-blind, randomized, parallel-group, controlled study of 423 adults with CF, subjects received either mannitol 400mg or mannitol 50mg (control), twice-daily via dry powder inhaler for 26 weeks.
Lead Product(s): Mannitol API
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Bronchitol
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2021
Details:
The unique delivery method of their xB3 platform has the potential to overcome a significant challenge in the treatment of many neurological disorders, which is the ability to cross the blood brain barrier.
Lead Product(s): Transcend-peptide
Therapeutic Area: Genetic Disease Product Name: xB3
Highest Development Status: UndisclosedProduct Type: Peptide
Recipient: Bioasis
Deal Size: $141.0 million Upfront Cash: $3.0 million
Deal Type: Licensing Agreement June 29, 2020
Details:
Chiesi Group expands distribution network via acquisition for worldwide product rights.
Lead Product(s): Deferiprone
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Apotex Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 13, 2020